Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Blood (2023) 142 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2023-188697

Published: 2023

Journal Articles

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Blood (2023) 142 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2023-188844

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Blood (2023) 142 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2023-187202

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Blood (2023) 142 (Supplement 1): 4710.

https://doi.org/10.1182/blood-2023-187453

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Blood (2023) 142 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2023-188672

Published: 2023

Journal Articles

Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study

Frances Seymour, Claire Taylor, Sharon Gilson, Catherine Olivier, Christopher Parrish, David Allan Cairns, Christopher Winder, Matt Clark, Lesley Smith, Andrew Scarsbrook, Charlotte Pawlyn, Graham Jackson, Gordon Cook

Blood (2023) 142 (Supplement 1): 6602.

https://doi.org/10.1182/blood-2023-184553

Published: 2023

Journal Articles

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

Gordon Cook, A J Ashcroft, Ethan R Senior, Catherine Olivier, Anna Hockaday, Jeanine Richards, James D. Cavenagh, John Snowden, Mark Drayson, Ruth M de Tute, Roger Owen, Kwee Yong, Mamta Garg, Kevin Boyd, Hamdi Sati, Sharon Gillson, Mark Cook, David Allan Cairns, Christopher Parrish

Blood (2023) 142 (Supplement 1): 783.

https://doi.org/10.1182/blood-2023-188532

Published: 2023

Journal Articles

GAS6 Promotes Robust Expansion of Human Hematopoietic Stem and Progenitor Cells with High Serial Engraftment Activity

Harinad B Maganti, Javed Manesia, Tanvir Hasan, Chelasea Mcgregor, Roya Pasha, David Allan, Julie Audet, Nicolas Pineault

Blood (2022) 140 (Supplement 1): 1979–1980.

https://doi.org/10.1182/blood-2022-169206

Published: 2022

Journal Articles

CRISPR Gene-Editing of Chemokine Receptors As a Novel Strategy to Redirect NK Cell Trafficking In Vivo

Emily R. Levy, PhD, Joseph Clara, MD, David Allan, PhD, Robert Reger, MS, Richard W. Childs, MD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-141408

Published: 2020

Journal Articles

High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells

Giacomo Waller, BS, David Allan, Dhana Chinnasamy, MSc, PhD, Mala Chakraborty, PhD, Emily Levy, MS, Michael Hochman, MD, Long Chen, MD PhD, Akkapon Poolcharoen, Georg Aue, Kate Stringaris, MD PhD, Robert Reger, MS, Richard Childs, MD

Blood (2017) 130 (Supplement 1): 5566.

https://doi.org/10.1182/blood.V130.Suppl_1.5566.5566

Published: 2017

Journal Articles

Increased Incidence of Venous Thromboembolism Following Allogeneic Compared with Autologous Hematopoietic Stem Cell Transplantation.

Andrew Gonsalves, Marc Carrier, MD, Philip Wells, MD, Sheryl McDiarmid, RN, Lothar Huebsch, MD, David Allan, MD

Blood (2007) 110 (11): 3986.

https://doi.org/10.1182/blood.V110.11.3986.3986

Published: 2007

Journal Articles

A Phase I Study with Long-Term Follow-Up of Autologous Stem Cell Transplantation Using Photodynamic Treatment of Marrow Grafts for Relapsed/Refractory Acute Leukemia.

David Allan, MD, Robert Belanger, MD, Lambert Busque, MD, Douglas Fish, MD, Jeannine Kassis, MD, Jean Roy, MD, Claude Perreault, MD, Denis-Claude Roy, MD

Blood (2005) 106 (11): 2201.

https://doi.org/10.1182/blood.V106.11.2201.2201

Published: 2005

Journal Articles

Mobilization of Endothelial Progenitor Cells in Autologous and Allogeneic Peripheral Blood Stem Cell Grafts.

David Allan, MD, Pascale Dubé, MSc, Jean Roy, MD, Denis-Claude Roy, MD

Blood (2005) 106 (11): 4231.

https://doi.org/10.1182/blood.V106.11.4231.4231

Published: 2005

NARROW

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients

Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Health-Related Quality of Life (HRQoL) in Patients with Genetic Standard and High-Risk Disease at Trial Entry: A Cross-Sectional Analysis of RADAR (UK-MRA Myeloma XV)

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study

Senescent Immune Signature in Frail and Vulnerable Newly Diagnosed Myeloma Patients: A Cohort Analysis from the UK-MRA Myeloma XIV Fitness Study

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

GAS6 Promotes Robust Expansion of Human Hematopoietic Stem and Progenitor Cells with High Serial Engraftment Activity

CRISPR Gene-Editing of Chemokine Receptors As a Novel Strategy to Redirect NK Cell Trafficking In Vivo

High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells

Increased Incidence of Venous Thromboembolism Following Allogeneic Compared with Autologous Hematopoietic Stem Cell Transplantation.

A Phase I Study with Long-Term Follow-Up of Autologous Stem Cell Transplantation Using Photodynamic Treatment of Marrow Grafts for Relapsed/Refractory Acute Leukemia.

Mobilization of Endothelial Progenitor Cells in Autologous and Allogeneic Peripheral Blood Stem Cell Grafts.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only